Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Our approach
Proprietary Technology
NeoVAC, our main product in development, which is aimed to enter the clinic in 2020, is developed utilizing our proprietary PersoVAC™, AmpliVax™, PyroVant™ and CADVax™ technologies.
Unique Differentiators
DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide/RNA vaccines, or cell-based immunotherapies.
Company Highlights
About Us
Company Background
Immunetune, based in Leiden, the Netherlands, is a dedicated and fast-moving biotech company committed to develop personalized, tumor-specific vaccines to fight cancer and prevent its recurrence.
News
Neoantigen Summit Europe, 20 – 22 April 2021
Our CEO, Gerben Zondag will present Immunetune's unique platform AmpliVax that enables time- and cost-efficient generation of personalized, DNA-based cancer vaccines at the upcoming digital Neoantigen Summit Europe on 20-22 Apri...
Bio-Europe Spring, 22-25 March 2021
We will attend the digital Bio-Europe Spring patnering meeting on 22 – 25 March 2021. Feel free to request a meeting if you’d like to hear more about possible partnering or investment opportunities.
Sachs Associates EU Life Sciences CEO Forum, 10 -11 March 2021
We will attend the digital Sachs Associates 14th European Life Sciences CEO Forum on 10-11 March 2021. Feel free to request a meeting if you’d like to hear more about possible partnering or investment opportunities.